Parkinson Disease Trends and Forecast
The future of the global parkinson disease market looks promising with opportunities in the carbidopa-levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, and anticholinergics markets. The global parkinson disease market is expected to reach an estimated $8.8 billion by 2030 with a CAGR of 6.1% from 2024 to 2030. The major drivers for this market are rising aging population, advances in diagnostic technologies, and increasing healthcare expenditure in emerging economies.
• Lucintel forecasts that, within the distribution channel category, retail pharmacy will remain the largest segment over the forecast period due to ease of availbility.
• In terms of region, North America will remain the largest region over the forecast period due to large number of important participants, high disposable income, high costs for healthcare, and an established healthcare system in this area.
Gain valuable insights for your business decisions with our comprehensive 150+ page report.
Emerging Trends in the Parkinson Disease Market
Emerging technologies and changing healthcare priorities are causing the market for Parkinson disease to change, with a number of defining trends occurring within the space. These trends present influencing pathways in shaping the future of treatments and care for Parkinson.
• Gene Therapy Development: Gene therapy is emerging as a potential game changer, aiming to address the underlying causes of Parkinson by modifying genes. Innovations such as AAV-mediated gene transfer are showing promise in reducing disease progression and improving patient outcomes.
• Advancing DBS Technology: Deep brain stimulation technology is continuously improving due to advancements in device design and programming. These newer systems of DBS permit more precise stimulation and greater customization, resulting in better symptom control and improved comfort for patients.
• Integration of Digital Health Solutions: From wearable devices to mobile applications, digital health technologies have become an intrinsic part of managing Parkinson disease patients. These tools assist in monitoring symptoms, adjusting treatment, and instantly providing information to health professionals.
• Focus on Personalized Medicine: The trend is toward personalized medicine, with therapies individualized to a patientÄX%$%Xs specific genetic profiles and characteristics. This approach aims to optimize therapeutic results while minimizing adverse events through personalized treatment approaches.
• Expansion of Clinical Trials: The increase in clinical trials for new therapies and interventions is expanding the treatment landscape. These trials are crucial for discovering innovative treatments and improving current therapeutic options.
Such emerging trends reshape the landscape of the Parkinson Disease marketplace through innovation, enhancement of personalization in treatments, and improvement in patient management. These trends provide a more dynamic and effective approach to Parkinson disease management.
Recent Developments in the Parkinson Disease Market
Recent developments in the Parkinson Disease market have come a long way with treatments, diagnostics, and patient care. Five key developments are discussed below:
• New Therapies: The introduction of new therapies such as levodopa-carbidopa intestinal gel and continuous infusion therapies is a major advancement. These therapies offer better symptom control and improvement in the quality of life for patients suffering from Parkinson Disease.
• Improvement of Deep Brain Stimulation: New DBS technologies are more precise and programmable, which has translated into better treatment outcomes. This development ensures finer control over motor symptoms, with minimal need for medication adjustments.
• Advances in Gene Therapy: New gene therapies, such as those based on AAV, aim to address the roots of Parkinson Disease. These treatments show promise in possibly impeding disease progression for potential long-term benefits.
• Integration of Digital Health Tools: Digital health solutions, including wearables and mobile applications, have been developed to provide symptom monitoring and better treatment management. These tools offer real-time data and facilitate communication between the patient and the health provider.
• Clinical Research Expansion: There is an increasing number of clinical trials with new therapies and interventions, leading to a growth in the options available for treatment. Continuous research is important for finding novel treatments and further enhancing current therapies.
These developments are advancing the Parkinson Disease market through the introduction of new therapies, the enhancement of available treatments, and the leveraging of technology for better patient care. They reflect ongoing efforts toward improved management of Parkinson Disease and better outcomes for patients.
Strategic Growth Opportunities for Parkinson Disease Market
The strategic growth opportunities in the Parkinson Disease market are driven by advancements in research, technology, and patient care. Five key growth opportunities include:
• Development of Disease-Modifying Therapies: Investing in research for disease-modifying therapies presents significant growth potential. These therapies aim to slow or halt disease progression, addressing a critical need in Parkinson care.
• Digital Health Solutions: The development and integration of digital health tools open pathways for growth. Wearable devices and mobile applications that track symptoms and treatment effectiveness play a role in improving patient management and engagement.
• Gene Therapy: The development of expanding gene therapy technologies will provide more viable long-term solutions for treating Parkinson; this may be a breakthrough in the treatment of the disease, targeting its root causes.
• Personalized Medicine: Growth is possible in developing personalized treatment profiles based on genetic and clinical parameters. Personalization in therapies will help improve success rates of treatments and enhance patient satisfaction.
• Increase in Global Clinical Trials: A greater number of global clinical trials for new treatments can hasten the development and market entry of drugs. This growth opportunity also embraces diversity in patient populations and geographies, improving the range of treatment options available.
These growth opportunities are set to influence the Parkinson Disease market through increased innovation, better patient management, and the expansion of choices in available treatments. They contribute significantly to the overall advancement and effectiveness in managing Parkinson disease.
Parkinson Disease Market Driver and Challenges
The market for Parkinson Disease is influenced by both drivers and challenges. These include technological, economic considerations, and regulatory aspects.
The factors responsible for driving the Parkinson disease market include:
• Research and Development: Continuous research on new therapies and technologies, such as gene therapy and deep brain stimulation, is considered a driver of market growth since this offers new treatment options, allowing for better patient outcomes.
• Increasing Population of Patients: The increasing prevalence of Parkinson Disease due to the aging population is expanding the market demand for effective treatments and management solutions.
• Increased Investments in Health Care: Significant investments in general health care by the public and private sectors for research into Parkinson and the development of drugs foster market growth. Investments support the creation of new therapies and the improvement of existing treatments.
• Integration of Digital Health Technologies: The adoption of digital health tools enhances symptomatic monitoring and management; hence, the market has grown as this improves treatment adherence for better patient care.
• Expansion of Global Clinical Trials: The growth in clinical trials across various geographic regions is broadening the range of available treatments and accelerating the development of new therapies, thus driving market growth.
Challenges in the Parkinson disease market include:
• High Treatment Cost of Innovative Therapies: The high costs associated with novel treatments, gene therapies, and sophisticated deep brain stimulation systems create barriers to access and affordability, particularly in low-income areas, which may impede market growth.
• Regulatory Barriers: Complex regulatory requirements and time-consuming procedures for new therapy approvals can act as disincentives to quick market entry and may result in delayed availability of innovative treatments.
• Economic Constraints: Economic downturns and budgetary constraints negatively affect spending on remedies for Parkinson; this can slow market growth and reduce investment in new therapies.
The drivers and challenges in the Parkinson Disease market reflect the dynamism of the industry. Addressing these factors is important to ensure further advancements in treatments, deliver quality patient care, and achieve continuity in market growth.
List of Parkinson Disease Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies parkinson disease companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the parkinson disease companies profiled in this report include-
• Cerevel Therapeutics
• Novartis
• Teva Pharmaceutical Industries
• Merck & Co.
• GlaxoSmithKline
• AbbVie
• H. Lundbeck
Parkinson Disease by Segment
The study includes a forecast for the global parkinson disease by drug class, distribution channel, and region.
Parkinson Disease Market by Drug Class [Analysis by Value from 2018 to 2030]:
• Carbidopa-Levodopa
• Dopamine Agonists
• MAO-B Inhibitors
• COMT Inhibitors
• Anticholinergics
• Others
Parkinson Disease Market by Distribution Channel [Analysis by Value from 2018 to 2030]:
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
Parkinson Disease Market by Region [Analysis by Value from 2018 to 2030]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
Country Wise Outlook for the Parkinson Disease Market
The Parkinson disease market is growing at a rapid rate due to innovations in treatments, diagnostics, and patient management. The major developments reflect significant milestones in drug therapies, technological solutions, and regional healthcare enhancements. A glimpse into some changes that have been happening in major markets recently:
• United States: The focus here is on the development of disease-modifying therapies and refined techniques for DBS. New medications, such as levodopa-carbidopa intestinal gel and other continuous infusion therapies, are significantly improving symptoms and enhancing lifestyles.
• China: China sees an increase in investment in research and development for Parkinson disease. Recent developments include the approval of new drugs and clinical trials expanding to advanced therapies. Treatment access is also improving, along with the management of patients.
• Germany: Germany leads in research on Parkinson disease, with newer studies focusing on gene therapy and advanced neuroimaging. Much emphasis is also placed on integrating digital health solutions and telemedicine into patient care for better treatment outcomes.
• India: India emphasizes better access to and increased awareness of Parkinson disease treatments. Recent developments include affordable generic medications and increased availability of rehabilitation services to support symptom management.
• Japan: Japan continues to advance care for Parkinson disease, with new drug approvals and advanced therapy treatments, including AAV-based gene therapies. There is also a focus on developing personalized treatment plans and integrating advanced diagnostic tools.
Features of the Global Parkinson Disease Market
Market Size Estimates: Parkinson disease market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Parkinson disease market size by drug class, distribution channel, and region in terms of value ($B).
Regional Analysis: Parkinson disease market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different drug class, distribution channel, and regions for the parkinson disease market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the parkinson disease market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.
FAQ
Q1. What is the parkinson disease market size?
Answer: The global parkinson disease market is expected to reach an estimated $8.8 billion by 2030.
Q2. What is the growth forecast for parkinson disease market?
Answer: The global parkinson disease market is expected to grow with a CAGR of 6.1% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the parkinson disease market?
Answer: The major drivers for this market are rising aging population, advances in diagnostic technologies, and increasing healthcare expenditure in emerging economies.
Q4. What are the major segments for parkinson disease market?
Answer: The future of the global parkinson disease market looks promising with opportunities in the carbidopa-levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, and anticholinergics markets.
Q5. Who are the key parkinson disease market companies?
Answer: Some of the key parkinson disease companies are as follows:
• Cerevel Therapeutics
• Novartis
• Teva Pharmaceutical Industries
• Merck & Co.
• GlaxoSmithKline
• AbbVie
• H. Lundbeck
Q6. Which parkinson disease market segment will be the largest in future?
Answer: Lucintel forecasts that retail pharmacy will remain the largest segment over the forecast period due to ease of availbility.
Q7. In parkinson disease market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period due to large number of important participants, high disposable income, high costs for healthcare, and an established healthcare system in this area.
Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the parkinson disease market by drug class (carbidopa-levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, anticholinergics, and others), distribution channel (hospital pharmacy, retail pharmacy, and online pharmacy), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Parkinson Disease Market, Parkinson Disease Market Size, Parkinson Disease Market Growth, Parkinson Disease Market Analysis, Parkinson Disease Market Report, Parkinson Disease Market Share, Parkinson Disease Market Trends, Parkinson Disease Market Forecast, Parkinson Disease Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.